As per letter enclosed.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Agarwals Eye Hospital reported Q2 FY26 revenue from operations of ₹117.72 Cr, up ~15% YoY from ₹102.19 Cr in Q2 FY25. H1 FY26 revenue stood at ₹234.64 Cr vs ₹202.21 Cr in H1 FY25. Net profit for Q2 jumped to ₹19.32 Cr (vs ₹14.15 Cr, ~37% YoY growth) and H1 PAT rose to ₹36.58 Cr (vs ₹28.26 Cr, ~29% YoY growth). EBITDA for Q2 was ₹40.76 Cr and H1 EBITDA was ₹78.69 Cr, with margins expanding to ~34% in Q2 from ~31% a year ago. The Board declared an interim dividend of ₹3 per share (30%) with record date November 7, 2025 and payment by November 29, 2025. The statutory auditor changed to S.R. Batliboi & Associates LLP, who issued an unmodified limited review report.
Strong earnings growth and margin expansion signal healthy operating momentum, while the ₹3 interim dividend offers near-term cash return to shareholders. The change in statutory auditor is a routine transition and the clean review report supports confidence in the numbers.